(2017)“Pharmacological modulation of Kv3.1 mitigates auditory midbrain temporal processing deficits following auditory nerve damage”, Scientific Reports7. doi:10.1038/s41598-017-17406-x.
(2019-06)“A balanced randomised placebo controlled blinded phase IIa multi-centre study to investigate the efficacy and safety of AUT00063 versus placebo in subjective tinnitus: The QUIET-1 trial”, Hearing Research377, p. 153–166. doi:10.1016/j.heares.2019.03.018.
(2018-04)“Effects of AUT00063, a Kv3.1 channel modulator, on noise-induced hyperactivity in the dorsal cochlear nucleus”, Hearing Research361, p. 36–44. doi:10.1016/j.heares.2018.01.017.